Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy

CA Meehan, E Cochran, A Kassai… - Expert review of …, 2016 - Taylor & Francis
CA Meehan, E Cochran, A Kassai, RJ Brown, P Gorden
Expert review of clinical pharmacology, 2016Taylor & Francis
The lipodystrophies represent a class of diseases characterized by leptin deficiency. Leptin
deficiency is associated with a severe form of the metabolic syndrome characterized by
dyslipidemia, insulin resistance, diabetes, and ovarian dysfunction. Metreleptin is the
pharmaceutical derived product that has been approved by the Food and Drug
Administration (FDA) to treat the severe metabolic abnormalities of the generalized forms of
lipodystrophy. Herein we describe the properties of metreleptin, its use in patients, which …
The lipodystrophies represent a class of diseases characterized by leptin deficiency. Leptin deficiency is associated with a severe form of the metabolic syndrome characterized by dyslipidemia, insulin resistance, diabetes, and ovarian dysfunction. Metreleptin is the pharmaceutical derived product that has been approved by the Food and Drug Administration (FDA) to treat the severe metabolic abnormalities of the generalized forms of lipodystrophy. Herein we describe the properties of metreleptin, its use in patients, which includes the administration of the drug and how it may be acquired by medical professionals as well as its safety, tolerability, and properties. Finally, we speculate on future uses and development of metreleptin.
Taylor & Francis Online